The occurrence of venous thromboembolism (VTE) in cancer patients is strongly associated with a poor cancer outcome irrespective of cancer stage [1]. Primary thromboprophylaxis with low-molecular weight heparin appears effective in cancer patients [2,3]; however, this treatment has several drawbacks, such as a need for daily injections and a significant bleeding risk, and has not been accepted nor advocated in guidelines for cancer patients. In cancer-free population evidence suggests that statin use is associated with a significant 20–30% reduction in VTE risk [4].
